List of Excipients in Branded Drug VIGABATRIN FOR ORAL SOLUTION

Generic Drugs Containing VIGABATRIN FOR ORAL SOLUTION

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	vigabatrin	31722-009	POVIDONE
Hikma Pharmaceuticals USA Inc	vigabatrin	0054-0702	POVIDONE
Granules Pharmaceuticals Inc	vigabatrin	70010-083	POVIDONE

What are the Most Frequently-Used Excipients in VIGABATRIN FOR ORAL SOLUTION?

# Of NDCs	Excipient
1	POVIDONE

Vigabatrin for Oral Solution: Excipient Strategy, Regulatory Barriers, and Commercial Opportunities

Last updated: August 15, 2026

Vigabatrin for oral solution is a specialized, high-complexity generic opportunity rather than a conventional oral-solid-dose product. The reference product, Sabril, uses single-dose 500 mg packets reconstituted with water. The commercial value of excipient innovation is therefore concentrated in dose uniformity, powder stability, reconstitution performance, pediatric usability, packaging, and manufacturing reliability.

The strongest opportunities are differentiated pediatric presentations, improved administration systems, and supply-chain advantages. Conventional formulation patenting is likely to provide limited protection because the reference powder product is compositionally simple and vigabatrin is an established active ingredient.

What is vigabatrin for oral solution used to treat?

Vigabatrin is an irreversible inhibitor of gamma-aminobutyric acid transaminase. In the United States, Sabril is approved for refractory complex partial seizures in patients aged two years and older and for infantile spasms in infants aged one month to two years. The oral-solution product is particularly important for infants and young children who cannot reliably swallow tablets.

The FDA-approved reference presentation is a 500 mg powder packet. The contents are dissolved in a specified volume of water before administration. Dosing may require partial packet administration, which makes dose preparation and measurement central to product performance.[1]

Attribute	Reference product profile
Active ingredient	Vigabatrin
Dosage form	Powder for oral solution
Strength	500 mg per single-dose packet
Primary users	Infants, children, and patients unable to swallow tablets
Administration	Reconstitution with water
Key clinical use	Infantile spasms and refractory complex partial seizures
U.S. regulatory pathway	NDA and generic ANDA pathways
Administration risk	Incorrect dilution or measurement of partial doses

Vigabatrin carries a serious retinal toxicity warning. The FDA requires a Risk Evaluation and Mitigation Strategy, including vision monitoring. The product is therefore regulated through a combination of drug-quality, labeling, dispensing, and patient-monitoring controls.[1]

What excipients are used in vigabatrin oral solution?

The commercial reference powder for oral solution is designed around a low-excipient or excipient-free architecture. The FDA labeling identifies the product as a white to off-white powder in single-dose packets and directs reconstitution with water.[1]

This design has several consequences:

1. Excipient changes can affect powder flow, moisture uptake, dissolution, and dose recovery.
2. Any new excipient can create additional comparative chemistry and stability work.
3. A formulation that adds taste-masking or suspending agents may introduce compatibility and pediatric tolerability issues.
4. A low-excipient formulation reduces safety concerns in infants but leaves fewer conventional differentiation points.

The central formulation question is not whether the product contains a large excipient platform. It is whether the manufacturer can improve the product without compromising the reference product's reconstitution behavior or regulatory comparability.

Candidate excipient functions

Excipient function	Potential materials	Commercial purpose	Main technical risk
Bulking or carrier material	Mannitol, lactose, microcrystalline cellulose	Improve powder handling and packet fill	Changes dose uniformity and dissolution
Flow aid	Colloidal silicon dioxide	Improve powder transfer and manufacturing flow	Dusting, segregation, and pediatric inhalation concerns
Binder or granulation aid	Povidone, low-substituted hydroxypropyl cellulose	Improve granule integrity	Slower dissolution or residual moisture
Sweetener	Sucralose, saccharin sodium, acesulfame potassium	Improve acceptability	Taste interaction, pediatric exposure, regulatory review
Flavor	Fruit flavors or masking systems	Improve adherence	Stability, allergen, and labeling complexity
Suspending agent	Xanthan gum, hypromellose	Maintain dose uniformity where suspension is used	Viscosity and incomplete container transfer
Buffer	Citrate or phosphate systems	Control pH after reconstitution	Chemical stability and compatibility
Wetting agent	Polysorbate or surfactant systems	Improve wetting of powder	Oxidation, impurity formation, and tolerability

The preferred strategy for a generic product is generally conservative: preserve the reference product's simple reconstitution profile, avoid unnecessary excipients, and focus differentiation on packaging, dose measurement, and manufacturing controls.

What excipient strategy is strongest for a commercial vigabatrin product?

A three-tier strategy is commercially relevant.

Tier 1: Reference-matched minimal-excipient powder

The lowest-risk product uses the fewest formulation changes possible. The objectives are:

• rapid and complete dissolution;
• consistent powder recovery from the packet;
• low moisture exposure;
• stable assay and impurity profile;
• reproducible partial-dose preparation;
• compatibility with the reference product's labeling and administration instructions.

This approach is best suited to an ANDA strategy where the product is positioned on price, supply reliability, and distribution access.

Tier 2: Pediatric acceptability formulation

A company can pursue improved palatability through sweeteners, flavor systems, or a more consumer-friendly reconstitution profile. This is commercially attractive because infantile spasms treatment can require repeated administration over prolonged periods.

The main limitation is that a taste-masked formulation may be clinically preferable but legally and technically more distant from the reference product. The sponsor must establish that added excipients do not alter bioavailability, dose uniformity, stability, or administration behavior. Pediatric excipient safety also receives heightened scrutiny under FDA and European regulatory standards.[2]

Tier 3: Administration-system differentiation

The strongest practical opportunity may be outside the powder composition. Examples include:

• calibrated oral syringes;
• dose-specific measuring devices;
• packet designs that reduce powder retention;
• child-resistant but caregiver-friendly packaging;
• visual reconstitution marks;
• unit-dose cartons organized by treatment day;
• multilingual preparation instructions;
• pharmacy dispensing configurations for partial packet dosing.

These features may support product differentiation without creating the same level of formulation risk as a new excipient system. Protection may arise through packaging, device, or method patents, although the commercial value depends on enforceability and market adoption.

What formulations are protected by vigabatrin patents?

Vigabatrin is an established small molecule with an earlier composition-of-matter patent estate. The principal commercial protection for the reference product historically came from drug patents, regulatory exclusivity, method-of-use claims, and the difficulty of supplying a safe pediatric product under restricted distribution conditions.

Formulation claims may cover:

• stable powder compositions;
• reconstitution systems;
• dose-measuring approaches;
• pediatric administration;
• packaging that limits moisture ingress;
• unit-dose delivery;
• methods for preparing partial doses;
• treatment of infantile spasms or refractory seizures.

The commercial significance of a formulation patent depends on whether it covers the active product actually sold, not merely an alternative laboratory composition. A patent directed to a flavored suspension has limited blocking value against a minimal-excipient powder product.

A current Orange Book review should distinguish between:

• listed patents for Sabril tablets;
• listed patents for Sabril powder for oral solution;
• method-of-use patents;
• patents that have expired;
• patents that remain listed but do not block all approved uses;
• patents subject to a Paragraph IV certification.

The FDA Orange Book is the controlling public source for listed patents and exclusivity associated with approved small-molecule products.[3]

When does vigabatrin lose exclusivity?

Vigabatrin's basic small-molecule exclusivity period has expired. The commercial question is no longer whether the active ingredient remains protected by ordinary new chemical entity exclusivity. The relevant issues are current Orange Book listings, remaining method-of-use rights, ANDA certifications, pediatric exclusivity, and product-specific regulatory requirements.

Exclusivity category	Vigabatrin relevance
New chemical entity exclusivity	Expired
Ordinary formulation exclusivity	Product-specific and dependent on FDA records
Orphan exclusivity	Potentially relevant only to the approved indication and statutory period
Pediatric exclusivity	Must be assessed against the relevant FDA grant
Patent exclusivity	Depends on live Orange Book listings and claim scope
REMS-related exclusivity	REMS does not itself create ordinary market exclusivity
Generic competition	Legally possible subject to ANDA approval and patent certifications

The absence of active composition-of-matter protection does not eliminate commercial barriers. Vigabatrin requires specialized manufacturing, pediatric labeling, safety monitoring, controlled distribution, and reliable supply.

Which companies are challenging vigabatrin exclusivity?

Generic competition has entered the U.S. market through ANDA approvals for vigabatrin products. Public FDA records, including the Approved Drug Products with Therapeutic Equivalence Evaluations database, identify approved generic products and their dosage forms.[3]

The main competitive groups are:

• established generic manufacturers with pediatric powder capabilities;
• specialty pharmaceutical companies that can support restricted-distribution products;
• contract manufacturers with sachet or stick-pack capacity;
• international suppliers seeking U.S. or European registration;
• branded suppliers maintaining commercial access through service and distribution infrastructure.

Paragraph IV risk is likely to be lower than for a newly launched blockbuster because the principal active-ingredient patents are old. Litigation exposure can still arise from method-of-use claims, formulation claims, certification disputes, and launch timing. A generic company should evaluate patent status separately for infantile spasms and refractory seizure indications because a skinny-label strategy may be possible where legally and commercially appropriate.

What is the FDA regulatory status of vigabatrin oral solution?

Sabril is an FDA-approved prescription product subject to a REMS program because of permanent vision-loss risk. The REMS requires prescriber, pharmacy, and patient controls, including ophthalmic monitoring.[1]

A generic manufacturer must address more than pharmaceutical equivalence. The product must fit the applicable restricted-distribution environment and support the same clinically relevant administration process. Key regulatory workstreams include:

• pharmaceutical equivalence;
• comparative dissolution and reconstitution;
• powder stability;
• packet integrity;
• dose uniformity;
• microbial quality;
• impurity control;
• container-closure performance;
• labeling and administration instructions;
• REMS implementation;
• pediatric excipient justification.

For a powder product, the quality dossier should give particular attention to moisture-mediated degradation, electrostatic powder retention, segregation during filling, and recovery from opened packets. These parameters can affect the delivered dose even when the assay of the bulk powder is within specification.

What commercial opportunities exist in vigabatrin oral solution?

The opportunity is specialized, with value concentrated in high service levels rather than broad volume.

Pediatric adherence

Taste, preparation time, and dosing accuracy are practical barriers for caregivers. A more acceptable flavor profile, simpler preparation, and calibrated dosing device could support premium positioning if the product remains within the approved regulatory framework.

Hospital and specialty-pharmacy supply

Hospitals and specialty pharmacies value dependable availability because treatment interruptions can be clinically serious. A supplier with dual-source active pharmaceutical ingredient capacity, validated packet manufacturing, and stable inventory may win contracts even without the lowest unit price.

Emerging-market access

Many markets have limited access to pediatric antiepileptic formulations. A lower-cost powder product with robust room-temperature stability and simple water reconstitution could support registrations in Latin America, Eastern Europe, Asia, and selected Middle Eastern markets.

Geographic expansion requires review of:

• national reference-product status;
• local patent registers;
• pediatric labeling;
• language and measuring-device rules;
• pharmacovigilance obligations;
• local manufacturing or tender requirements;
• controlled-distribution implementation.

Lifecycle management

Lifecycle products may include:

• 250 mg unit-dose packets;
• ready-to-use oral suspensions;
• single-use sachets;
• premeasured caregiver kits;
• hospital-use presentation sizes;
• co-packaged oral syringes;
• stability-enhanced packaging.

A 250 mg packet could reduce partial-packet dosing errors, but it would require a separate regulatory and commercial assessment. It would also compete against the operational simplicity of the existing 500 mg packet format.

How strong is the patent estate for vigabatrin oral solution?

The patent estate is likely weaker at the active-ingredient level and stronger around selected product implementations. The most defensible new intellectual property would be tied to a demonstrated technical advantage, such as:

• improved moisture protection;
• reduced powder retention;
• reproducible partial-dose delivery;
• improved reconstitution time;
• validated pediatric palatability;
• stable ready-to-use suspension;
• integrated dosing device;
• packaging that supports compliance with REMS procedures.

A weak strategy would rely on broad claims covering ordinary excipients without a measurable performance benefit. Such claims face validity and obviousness risks, particularly for an established active ingredient and familiar pediatric dosage form.

What generic launch risks exist for vigabatrin oral solution?

Risk	Business effect	Mitigation focus
REMS execution failure	Restricted dispensing or delayed launch	Early pharmacy and patient-service implementation
Powder instability	Batch failure and recalls	Moisture-control packaging and accelerated stability
Partial-dose errors	Medication errors and complaints	Calibrated devices and clear instructions
Taste rejection	Poor adherence	Controlled palatability development
Limited market size	Weak return on investment	Specialty-channel contracts and geographic expansion
API supply disruption	Stock-outs	Qualified second source and inventory buffers
Patent or labeling dispute	Launch delay or indication limits	Claim-by-claim and use-by-use clearance
Manufacturing complexity	Higher cost per unit	High-yield packet filling and automation

No public product-level revenue figure provides a reliable basis for valuing the entire vigabatrin oral-solution market. Revenue exposure is concentrated in a narrow patient population, but the product can command strategic value because it addresses a serious pediatric indication with limited formulation alternatives.

Key Takeaways

• Vigabatrin for oral solution is a specialized pediatric product built around a 500 mg powder packet and water reconstitution.
• The most defensible generic strategy is a minimal-excipient, reference-matched formulation with strong moisture, dose-uniformity, and packet-performance controls.
• Taste masking and new excipients create commercial differentiation but increase regulatory and comparability risk.
• Packaging, oral syringes, reconstitution aids, and caregiver instructions may offer better risk-adjusted opportunities than a complex excipient platform.
• Basic active-ingredient exclusivity has expired; current commercial clearance depends on live patents, method-of-use claims, labeling, and REMS requirements.
• The opportunity is more attractive for specialty generic companies, pediatric formulation developers, and suppliers with reliable restricted-distribution infrastructure than for high-volume generic manufacturers.
• Geographic expansion and improved pediatric administration systems are the clearest lifecycle opportunities.

FAQs

Can a company add flavor to vigabatrin oral solution?

Yes, but the flavor system must be evaluated for pediatric safety, chemical compatibility, stability, taste masking, and regulatory acceptability. Flavoring may require new comparative data and can reduce the simplicity of an ANDA strategy.

Is a ready-to-use vigabatrin suspension commercially attractive?

It may be attractive for caregivers and institutions because it eliminates reconstitution. The principal barriers are chemical stability, preservative selection, microbial control, packaging, shelf life, and potential regulatory distance from the powder reference product.

Does a new oral syringe create patent value for vigabatrin?

A syringe can support device or packaging claims if it solves a specific dosing problem and meets patentability standards. Its commercial value is strongest when it improves partial-dose accuracy or reduces caregiver preparation errors.

Are biosimilars relevant to vigabatrin?

No. Vigabatrin is a chemically synthesized small molecule, so competition proceeds through generic drug pathways rather than biosimilar approval under the Public Health Service Act. The relevant U.S. pathway is generally an ANDA, subject to pharmaceutical equivalence and patent certifications.[3]

What is the best manufacturing advantage for vigabatrin oral solution?

The strongest advantage is reliable single-dose packet production with low powder loss, strong moisture protection, consistent reconstitution, and dependable supply under specialty-distribution requirements.

References

1. U.S. Food and Drug Administration. (2023). Sabril (vigabatrin) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2016). Use of inactive ingredients in approved drug products in pediatric patients. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. European Medicines Agency. (2023). Guideline on pharmaceutical development of medicines for paediatric use. EMA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. USP Convention.